세계의 체외진단(IVD) 시장 : 동향과 시장 최신 정보(2025년)

Kalorama Information's "In Vitro Diagnostic (IVD) Trends and Market Update, 2025" provides the latest insights into the dynamic IVD market amid ongoing economic and global uncertainties. Published twice a year-first in April 2025 and again in Q4 2025, following the release of Kalorama's annual 1,600-page study, "The Worldwide Market for In Vitro Diagnostics (IVD), 18th Edition"-this report serves both as a standalone resource and a companion to Kalorama's annual flagship IVD analysis.

In 2024, the IVD market continued to expand, with most segments experiencing growth, despite the decline in COVID-19 testing revenues. AI-driven innovations, regulatory shifts, and changes in global healthcare spending are shaping the competitive landscape, reinforcing the resilience of the IVD sector.

Key growth areas attracting industry attention and that are anticipated to play a significant role in the future of IVD include:

This report delivers timely and actionable intelligence, covering:

• Market drivers and major industry trends
• New product developments shaping IVD innovation
• Competitive landscape insights and activities of key players
• Emerging opportunities and strategic growth areas

With a commitment to delivering precise and up-to-date market intelligence, Kalorama Information continues to provide industry stakeholders with critical data and expert analysis to navigate the ever-evolving IVD landscape.

Table of Contents

Chapter 1: Worldwide IVD Market Update - April 2025

• IVD Market Demand and Growth
  • Figure 1-1: Segment Performance Commentary, Q1-Q4 2024
  • Table 1-1: Global In Vitro Diagnostic Sales, by Product Market, 2024 ($ million) [Blood bank molecular - NAT Screens, Blood grouping/typing, Circulating tumor cells, Clinical Chemistry, Coagulation (PT/INR), Coagulation, molecular, D-dimer, Hematology - Core Lab, Histology/cytology, HPV, molecular, Immunoassays - non-isotopic (Immuno - Infectious disease, Other immune, Immuno - Blood bank screening, Drugs of Abuse, Diabetes HbA1c, lab), Mass Spectrometry, Microbiology (ID/AST), Microbiology (molecular), Microbiology - Mass Spectrometry, Nucleic acid assays/genetic tests, Other (transplant testing, other, etc.), POC, OTC diabetes, POC, OTC other, POC, professional/hospital]
  • Figure 1-2: Quarterly IVD Segment Performance, by Segment, Q1 2024 - Q4 2024 ($ million) [Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other]
  • Figure 1-3: IVD Segment Performance, Total Market Value, 2024 ($ million) [Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other]
• COVID-19 Diagnostic Markets
  • Table 1-2: COVID-19 Product Sales, 2024 ($ million) [Immunoassay (Antigen, Serology), Molecular, Rapid]
• Effect of COVID-19 on Market Segments
  • Table 1-3: IVD Market Excluding and with COVID-19, 2024 ($ million)
  • Figure 1-4: IVD Market Distribution, by Segment, 2024 (%) [IVD Market Excluding COVID-19 Assays and Instruments, COVID-19 Assays and Instruments]
  • Figure 1-5: IVD Market by COVID-19 and non-COVID Markets, Quarterly Performance, 2024 ($ million) [IVD Market Excluding COVID-19 Assays and Instruments, COVID-19 Assays and Instruments]
  • Table 1-4: Global In Vitro Diagnostic Market, YoY Growth 2023-2024 (%) [Blood bank molecular - NAT Screens, Blood grouping/typing, Circulating tumor cells, Clinical Chemistry, Coagulation (PT/INR), Coagulation, molecular, D-dimer, Hematology - Core Lab, Histology/cytology, HPV, molecular, Immunoassays - non-isotopic (Immuno - Infectious disease, Other immune, Immuno - Blood bank screening, Drugs of Abuse, Diabetes HbA1c, lab), Mass Spectrometry, Microbiology (ID/AST), Microbiology (molecular), Microbiology - Mass Spectrometry, Nucleic acid assays/genetic tests, Other (transplant testing, other, etc.), POC, OTC diabetes, POC, OTC other, POC, professional/hospital]
  • Figure 1-6: Global In Vitro Diagnostic Market - YoY Growth 2023-2024 (%) [Blood bank molecular - NAT Screens, Blood grouping/typing, Circulating tumor cells, Clinical Chemistry, Coagulation (PT/INR), Coagulation, molecular, D-dimer, Hematology - Core Lab, Histology/cytology, HPV, molecular, Immunoassays - non-isotopic (Immuno - Infectious disease, Other immune, Immuno - Blood bank screening, Drugs of Abuse, Diabetes HbA1c, lab), Mass Spectrometry, Microbiology (ID/AST), Microbiology (molecular), Microbiology - Mass Spectrometry, Nucleic acid assays/genetic tests, Other (transplant testing, other, etc.), POC, OTC diabetes, POC, OTC other, POC, professional/hospital]

Chapter 2: Product Trends and New Developments

• Liquid Biopsy
• Mass Spectrometry
• Immunoassay
• Molecular
• Personalized Medicine
• POC
• Sequencing
• Antigen/Antibody
• Molecular

Chapter 3: Top IVD Market Participant Results

• Selected Competitive Leader Updates
  • Figure 3-1: IVD Segment Growth by Leading Competitors, Change in Sales 2023-2024 (%) [Abbott Diagnostics, Becton Dickinson, bioMerieux, Danaher, Dexcom, QuidelOrtho, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific]
  • Figure 3-2: IVD Sales Changes in Market Distribution, 2021-2024 - Roche and Abbott Battle for #1 Spot (%) [Abbott Diagnostics, Becton Dickinson, bioMerieux, Danaher, Dexcom, Exact Sciences, Hologic, QuidelOrtho, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific, Werfen, Others]
  • Figure 3-3: Comparison of Total Diagnostic Sales for Abbott vs Roche, 2022-2024 ($ million)
• Q4 2024, Q1 2025 M&A Activity
  • Table 3-1: Q4 2024, Q1 2025 Merger and Acquisition Activity
• Abbott Laboratories
  • Table 3-2: Abbott Corporate Summary
• Becton Dickinson and Co
  • Table 3-3: Becton Dickinson Corporate Summary
• bioMerieux SA
  • Table 3-4: bioMerieux Corporate Summary
• Danaher Corporation
  • Table 3-5: Danaher Corporation Summary
• Dexcom, Inc
  • Table 3-6: Dexcom Corporate Summary
• Exact Sciences
  • Table 3-7: Exact Sciences Corporate Summary
• QuidelOrtho Corporation
  • Table 3-8: QuidelOrtho Corporate Summary
• Roche Diagnostic
  • Table 3-9: Roche Diagnostic Corporate Summary
• Siemens Healthineers
  • Table 3-10: Siemens Healthineers Corporate Summary
• Sysmex Corporation
  • Table 3-11: Sysmex Corporate Summary
• Thermo Fisher Scientific
  • Table 3-12: Thermo Fisher Scientific Corporate Summary

Chapter 4: New Opportunities

• Staffing Shortages
• LDT Update
• IVDR Compliance Deadline Approaches
  • Table 4-1: IVDR New Risk-based Classification System
• Telemedicine